Skip to content
Press Releases
Filter Releases
EMERYVILLE, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the completion of a Phase 1 clinical trial of ADS-4101, an investigational drug in development for the treatment of partial onset seizures in patients with epilepsy. Derived from the Company's development platform, ADS-4101 is chrono-s...
Jan 3, 2017 General Releases HTML PDF